Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-26T20:10:04.216Z Has data issue: false hasContentIssue false
  • English
  • Français

Polysubstance Use After Frontal Lobe Syndrome: A Case Report

Published online by Cambridge University Press:  01 September 2022

M. Ulusoy  and
M. Ergelen
M. Ulusoy*
Affiliation:
Ankara University Faculty of Medicine, Department Of Psychiatry, Ankara, Turkey
M. Ergelen
Affiliation:
Istanbul Erenkoy Training and Resarch Hospital for Psychiatry and Neurological Diseases, Department Of Psychiatry, Istanbul, Turkey
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Frontal lobe syndrome (FLS) is a clinical condition characterized by personality and behavioral changes that usually occur after a traumatic brain injury (TBI). The main features of this syndrome are related to the deterioration of basic functions of the frontal lobe. Substance use disorder (SUD) is rare but also serious comorbiditiy seen after TBI.

Objectives

In this case report, we aimed to discuss a case who developed SUD after TBI.

Methods

Case report

Results

A 40-year-old male patient with history of using cannabis, methamphetamine, synthetic cannabinoid was admitted to our alcohol and substance use disorders research and treatment centre (AMATEM) inpatient unit for detoxification. He has reported that he was injured by a car accident five years ago, had a surgery and was hospitalized for a few months, and started to use substance to relieve pain. According to the medical records, the left frontal and temporoparietal regions were affected. He reported no history of substance abuse before injury, no previous history of psychiatric admission. Personality and behavior changes had been observed after TBI. In the first examination he had depressed mood and loss of interest. Sertraline (gradually titrated up to 150 mg/d) and risperidone (1 mg/d) were started. Also N-acetylcysteine (1,200 mg/d) was added to reduce craving and drug-seeking behaviours for four weeks.

Conclusions

Frontal lobe syndrome and TBI may differ in terms of clinical presentations. Substance use may be a way to cope with mental, cognitive or behavioural changes, psychosocial stressors, anxiety, sleep problems or pain after TBI.

Disclosure

No significant relationships.

Keywords

substance abusefrontal lobe syndrometraumatic brain injury
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S827 - S828
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.